Sunday, September 20, 2026

Aurora Cannabis Stock Plummets 12%: Investors Wary Amid Bearish Momentum

ViaNews Editorial Team

September 18, 2023

Aurora Cannabis Stock Plummets 12%: Investors Wary Amid Bearish Momentum

(VIANEWS) - Aurora Cannabis (NYSE: ACB) shares dropped 12.39% at 14:02 EST Monday after four consecutive sessions of gains, despite the overall market rising 0.06% and reaching EUR15,983.72. This decline came despite signs that overall sentiment had turned bullish despite rising 0.06 points to EUR15,983.72.

About Aurora Cannabis

Aurora Cannabis Inc. is a premier producer and distributor of medical and recreational cannabis and related products in Canada and internationally, operating through three segments: Canadian Cannabis, European Cannabis and Plant Propagation. Products offered include dried cannabis, cannabis oils, capsules, edibles, extracts and soft gels. Aurora also provides hemp-derived CBD products, propagated vegetables and ornamental plants as well as distribution services for wholesale medical cannabis in Europe, Australia, South America and other international markets. Aurora Cannabis Inc's adult-use brand portfolio consists of Aurora Drift, San Rafael '71 Daily Special Whistler Being Greybeard as well as CBD brands Reliva and KG7 for adult-use as well as medical cannabis brands MedReleaf CanniMed Aurora Whistler Medical Marijuana Co Pedanios Bidiol CraftPlant for medical use. Aurora Cannabis Inc's headquarters can be found in Leduc, Canada.

Technical Analysis

Aurora Cannabis (ACB) saw an unprecedented trading volume today of 347,091,460 shares - 108.06% above its usual volume of 166,816,000. This increase could indicate increased interest and could cause volatility to increase further in its stock price. Aurora Cannabis stock has experienced negative 3.08% intraday variation average over the last week, positive 3.87% average monthly volatility, and positive 4.61% quarterly average volatility over its recent history. Aurora Cannabis also experienced 10.26% weekly amplitude volatility versus 8.62% monthly and 4.61 % quarter averages over this time frame. Investors should pay careful attention to fluctuations in stock volatility as this could signal potential trading or investing opportunities in that stock. But keep in mind that volatility may also be caused by other factors, including changes in market sentiment, company news releases and macroeconomic forces - therefore conducting thorough research before making any definitive investment decisions is always recommended.

Equity Analysis

Aurora Cannabis's trailing twelve months EPS of EUR-6.81 indicates a loss per share over the past year and should be taken into account when assessing its financial performance and future profitability potential. Aurora Cannabis operates in an intensely competitive and rapidly expanding cannabis industry, which may significantly impact short-term profitability. However, long-term growth potential presents opportunities to investors who can tolerate taking on some short-term risk by investing in Aurora Cannabis. Investors evaluating Aurora Cannabis should also take into account other financial metrics, including revenue growth, cash flow and debt levels when assessing its investment potential. Comparing Aurora Cannabis's financials against those of competitors within its industry may also prove useful.

More news about Aurora Cannabis (ACB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com